Molecular biomarkers of Parkinson disease and neurodegenerative disorders in cerebrospinal fluid

Katayama, Takayuki; Takeguchi, S.; Kano, Kohei; Asanome, Akira; Takahashi, Kihito; Saito, Tsukasa; Sawada, Jun; Naoyuki, Hasui

doi:10.1016/j.jns.2017.08.1020

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neurodegenerative protein markers associate with NDD but do not correlate to vCSF-cfmtDNA levels. To further assess the links between vCSF-cfmtDNA and neurodegeneration we compared cfmtDNA levels to the abundance of CSF protein markers of neurodegeneration 43,44 , including neuron-specific enolase (NSE) 45,46 , 14-3-3 zeta and 14-3-3 beta 47 , alpha-synuclein 48,49 and tropomyosin receptor kinase B (TRKB) 50,51 . To investigate potential associations with mitochondrial debris, extracellular and/or synaptic vesicles, vCSF-cfmtDNA was compared to the levels of the most abundant synaptic vesicle membrane protein synaptophysin [52][53][54] and mitochondrial markers: SDHA (an inner mitochondrial membrane marker) 55 , TFAM (a mitochondrial transcription factor, the expression of which often reflects mtDNA level) 56 and porin (to investigate mitochondrial mass) 57 .…”

Section: Vcsf-cfmtdna Is Increased In Patients Exhibiting Neocorticalmentioning

confidence: 99%

Post-mortem ventricular cerebrospinal fluid cell-free-mtDNA in neurodegenerative disease

Lowes

Kurzawa‐Akanbi

Pyle

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Cell-free mitochondrial DNA (cfmtDNA) is detectable in almost all human body fluids and has been associated with the onset and progression of several complex traits. In-life assessments indicate that reduced cfmtDNA is a feature of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and multiple sclerosis. However, whether this feature is conserved across all neurodegenerative diseases and how it relates to the neurodegenerative processes remains unclear. In this study, we assessed the levels of ventricular cerebrospinal fluid-cfmtDNA (vCSF-cfmtDNA) in a diverse group of neurodegenerative diseases (NDDs) to determine if the in-life observations of reduced cfmtDNA seen in lumbar CSF translated to the post-mortem ventricular CSF. To investigate further, we compared vCSF-cfmtDNA levels to known protein markers of neurodegeneration, synaptic vesicles and mitochondrial integrity. Our data indicate that reduced vCSF-cfmtDNA is a feature specific to Parkinson’s and appears consistent throughout the disease course. Interestingly, we observed increased vCSF-cfmtDNA in the more neuropathologically severe NDD cases, but no association to protein markers of neurodegeneration, suggesting that vCSF-cfmtDNA release is more complex than mere cellular debris produced following neuronal death. We conclude that vCSF-cfmtDNA is reduced in PD, but not other NDDs, and appears to correlate to pathology. Although its utility as a prognostic biomarker is limited, our data indicate that higher levels of vCSF-cfmtDNA is associated with more severe clinical presentations; suggesting that it is associated with the neurodegenerative process. However, as vCSF-cfmtDNA does not appear to correlate to established indicators of neurodegeneration or indeed indicators of mitochondrial mass, further work to elucidate its exact role is needed.

show abstract

Section: Vcsf-cfmtdna Is Increased In Patients Exhibiting Neocorticalmentioning

confidence: 99%

Post-mortem ventricular cerebrospinal fluid cell-free-mtDNA in neurodegenerative disease

Lowes

Kurzawa‐Akanbi

Pyle

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

Molecular biomarkers of Parkinson disease and neurodegenerative disorders in cerebrospinal fluid

Cited by 1 publication

References 0 publications

Post-mortem ventricular cerebrospinal fluid cell-free-mtDNA in neurodegenerative disease

Post-mortem ventricular cerebrospinal fluid cell-free-mtDNA in neurodegenerative disease

Contact Info

Product

Resources

About